Abstract
We previously reported that transcription-coupled repair (TCR)-deficient human fibroblasts are extremely sensitive to UV-induced apoptosis and this sensitivity correlated with the induction of the p53 tumour suppressor. However, we have also found that p53 can be protective against UV-induced apoptosis. Thus, prior to this study, it was not clear whether the induction of p53 in TCR-deficient fibroblasts contributed to their death. To address this issue, we have expressed human papillomavirus E6 (HPV-E6) in primary fibroblasts derived from patients affected with xeroderma pigmentosum (complementation groups A, B and C) and Cockayne syndrome (complementation group B). We found that TCR-deficient (XP-A, XP-B and CS-B) fibroblasts were more sensitive than TCR-proficient cells (XP-C and normal) to both UV light and cisplatin treatment and this increase in sensitivity was not p53 dependent. Importantly, HPV-E6 expression increased the sensitivity of TCR-proficient normal and XP-C fibroblasts to UV- and cisplatin-induced apoptosis. This increase in sensitivity correlated with a decrease in the capacity of HPV-E6 expressing cells to recover mRNA synthesis following UV-irradiation. Therefore, we propose that p53 protects against UV- and cisplatin-induced apoptosis in a TCR-dependent manner and that p53 does not contribute strongly to the induction of apoptosis in TCR-deficient fibroblasts.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Andera L, Wasylyk B . 1997 Mol. Med. 3: 852–863
Barley RDC, Enns L, Paterson MC, Mirzayans R . 1998 Oncogene 17: 533–543
Conforti G, Nardo T, D'Incalci M, Stefanini M . 2000 Oncogene 19: 2714–2720
Cullinane C, Mazur SJ, Essigmann JM, Phillips DR, Bohr VA . 1999 Biochemisry 38: 6204–6212
El-Mahdy M, Hamada F, Wani M, Zhu Q, Wani A . 2000 Mutat. Res. 459: 135–145
Ford JM, Hanawalt PC . 1997 J. Biol. Chem. 272: 28073–28080
Friedberg E, Walker G, Siede W . 1995 DNA Repair and Mutagenesis ASM Press, Washington, DC
Koumenis C, Giaccia A . 1997 Mol. Cell. Biol. 17: 7306–7316
Lackinger D, Eichhorn U, Kaina B . 2001 Mutagenesis 16: 233–241
Lackinger D, Kaina B . 2000 Mutat. Res. 457: 113–123
Levine AJ . 1997 Cell 88: 323–331
Ljungman M, Zhang F . 1996 Oncogene 13: 823–831
Ljungman M, Zhang F, Chen F, Rainbow A, McKay B . 1999 Oncogene 18: 583–592
Lowe SW, Lin AW . 2000 Carcinogenesis 21: 485–495
Malkin D . 1994 Biochim. Biophys. Acta 1198: 197–213
May A, Nairn RS, Okumoto DS, Wassermann K, Stevnsner T, Jones JC, Bohr VA . 1993 J. Biol. Chem. 268: 1650–1657
McKay BC, Chen F, Clarke ST, Wiggin HE, Harvey LM, Ljungman M . 2001 Mutat. Res. 485: 93–105
McKay BC, Chen F, Perumalswami CR, Zhang F, Ljungman M . 2000 Mol. Biol. Cell 11: 2543–2551
McKay BC, Francis MA, Rainbow AJ . 1997a Carcinogenesis 18: 245–249
McKay BC, Ljungman M . 1999 Neoplasia 1: 276–284
McKay BC, Ljungman M, Rainbow AJ . 1998 Oncogene 17: 545–555
McKay BC, Ljungman M, Rainbow AJ . 1999 Carcinogenesis 20: 1389–1396
McKay BC, Winrow C, Rainbow AJ . 1997b Photochem. Photobiol. 66: 659–664
Mello JA, Lippard SJ, Essigmann JM. (1995) . Biochemistry 34: 14783–14791
Mirzayans R, Enns L, Dietrich K, Barley RDC, Paterson MC . 1996 Carcinogenesis 17: 691–698
Selby CP, Drapkin R, Rainberg D, Sancar A . 1997 Nucleic Acids Res. 25: 787–793
Smith ML, Chen IT, Zhan QM, O'Connor PM, Fornace AJ . 1995 Oncogene 10: 1053–1059
Smith ML, Fornace AJ . 1996 Am. J. Pathol. 148: 1019–1022
Smith ML, Fornace AJ . 1997 Proc. Natl. Acad. Sci. USA 94: 12255–12257
Therrien J-P, Drouin R, Baril C, Drobetsky EA . 1999 Proc. Natl. Acad. Sci. USA 96: 15038–15043
Thomas M, Pim D, Banks L . 1999 Oncogene 18: 7690–7700
van Hoffen A, Natarajan A, Mayne L, van Zeeland A, Mullenders L, Venema J . 1993 Nucleic Acids Res. 21: 5890–5895
Vogelstein B, Lane D, Levine AJ . 2000 Nature 408: 307–310
Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly JM, Wang Z, Friedberg EC, Evans MK, Taffe BG, Bohr VA, Weeda G, Hoeijmakers JHJ, Forrester K, Harris CC . 1995 Nat. Genet. 10: 188–195
Wani MA, Zhu QZ, El-Mahdy M, Wani AA . 1999 Carcinogenesis 20: 765–772
Yamaizumi M, Sugano T . 1994 Oncogene 9: 2775–2784
Acknowledgements
We would like to thank Drs Christina Addison (Ottawa Regional Cancer Centre), Steve Ethier (University of Michigan), Denise Galloway (Fred Hutchinson Cancer Center), Doug Gray (Ottawa Regional Cancer Centre) and Theodore Lawrence (University of Michigan) for cell lines and viral constructs. We would also like to thank the staff at the flow cytometic core facility at the University of Michigan. This work was supported by a grant from the National Institutes of Health (CA82376-01) to M Ljungman and Cancer Care Ontario to BC McKay.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McKay, B., Becerril, C. & Ljungman, M. P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts. Oncogene 20, 6805–6808 (2001). https://doi.org/10.1038/sj.onc.1204901
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204901
Keywords
This article is cited by
-
Comparison of responsiveness to cancer development and anti-cancer drug in three different C57BL/6N stocks
Laboratory Animal Research (2019)
-
PRAP1 is a novel executor of p53-dependent mechanisms in cell survival after DNA damage
Cell Death & Disease (2012)
-
p53 inhibits mRNA 3′ processing through its interaction with the CstF/BARD1 complex
Oncogene (2011)
-
Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin
BMC Cancer (2010)
-
Proteasome-mediated degradation of Tob is pivotal for triggering UV-induced apoptosis
Oncogene (2009)